GMA301

 

GMA301

-

 

Endothelin receptor A/endothelin-1 axis is associated with pulmonary artery hypertension (PAH) and has been targeted for the treatment of PAH.  GMA301 is a humanized monoclonal antibody against endothelin receptor A, may become the first long-lasting PAH drug with better efficacy and less adverse effects.


 We have finished  phase Ⅰa clinical studies in Australia and currently conducting a multi-center China-US phaseⅠb trial.